Latest news with #EuronextGrowth®
Business Wire
29-07-2025
- Business
- Business Wire
SEMCO Technologies Confirms the Success of Its IPO With the Exercise of the €1.2 Million Over-Allotment Option, Bringing the Final Amount of the Offering to €46.2 Million
CASTRIES, France--(BUSINESS WIRE)--Regulatory News: SEMCO Technologies (ISIN: FR0014010H01; Ticker: ALSEM), a company specializing in the design and manufacture of strategic components for the production of semiconductors, announces that, in view of the strong demand expressed in the context of its initial public offering on the Euronext Growth ® market in Paris, CIC Market Solutions, acting as stabilising agent on behalf of and for the account of the Lead Managers and Associate Bookrunners, has exercised the Over-allotment Option in the amount of €1.2 million, resulting in the sale by ECM Technologies, the main shareholder of SEMCO Technologies, of 80,000 existing Shares at the offer price (€15.00 per share), bringing the total size of the offering to €46.2 million. The total number of shares offered in the IPO was 3,079,999, including 266,666 new shares and 2,813,333 shares sold as part of the Offer, the extension clause and the over-allotment option. As a result, the free float now represents approximately 29.9% of SEMCO Technologies' share capital. BREAKDOWN OF THE COMPANY'S CAPITAL AND VOTING RIGHTS Following the IPO and the exercise of the Over-Allotment Option, the distribution of SEMCO Technologies' share capital and voting rights is as follows: LIQUIDITY CONTRACT SEMCO Technologies also announces that it has entrusted Gilbert Dupont with the implementation of a liquidity contract in accordance with the decision of the French Financial Markets Authority (Autorité des marchés financiers) No. 2018-01 of 2 July 2018, applicable since 1 January 2019, establishing liquidity contracts on equity securities as an accepted market practice 3. The liquidity contract will take effect on 29 July 2025, with €400,000 in cash allocated to the liquidity account. END OF THE STABILISATION PERIOD WITH AN EARLY CLOSING ON 28 JULY 2025 The stabilisation period, which began on 9 July 2025, ended early on 28 July 2025. CIC Market Solutions, acting as stabilising agent on behalf of and for the account of the Lead Managers and Joint Bookrunners for the IPO, declares that it has not carried out any stabilisation transactions and has therefore exercised the Over-allotment Option in the amount of €1.2 million, resulting in the sale by ECM Technologies, the main shareholder of SEMCO Technologies, of 80,000 existing Shares at the offer price (€15.00 per share), bringing the total size of the placement to €46.2 million. The total number of shares offered in the IPO was 3,079,999, including 266,666 new shares and 2,813,333 shares sold under the Offer, the extension clause and the over-allotment option. As a result, the free float now represents approximately 29.9% of SEMCO Technologies' share capital. FINANCIAL INTERMEDIARIES AND ADVISORS Next financial announcement: half-year results for 2025, 25 September 2025 – after market close. About SEMCO Technologies SEMCO Technologies is a French company specializing in the design and manufacture of components essential to the production of next-generation semiconductors, electrostatic chucks (eChucks). With 30 years of expertise and unique technological know-how, SEMCO Technologies designs high-tech, custom-made eChucks, distinguishing itself from generalist manufacturers by its ability to meet the most demanding market requirements. Founded in 1986 in Montpellier, it became a wholly-owned subsidiary of the ECM Group in 2016, a family-owned group and world leader in the manufacture of equipment for the treatment and transformation of materials. SEMCO Technologies achieved a turnover of €26.4 million 4 on December 31, 2024. For more information: Disclaimer This press release contains forward-looking statements, not historical facts, and should not be interpreted as a guarantee that the events and data stated will occur. These forward-looking statements are based on data, assumptions and estimates that SEMCO Technologies considers reasonable. SEMCO Technologies operates in a competitive and rapidly changing environment. The company is therefore unable to anticipate all risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the occurrence of a risk or combination of risks could lead to results that differ significantly from those mentioned in any forward-looking statement. SEMCO Technologies draws your attention to the fact that forward-looking statements are not guarantees of future performance and that its actual financial position, results and cash flows, as well as the development of the sector in which SEMCO Technologies operates, may differ significantly from those proposed or suggested by the forward-looking statements contained in this document. Furthermore, even if the financial situation, results, cash flows and developments in the sector in which SEMCO Technologies operates are in line with the forward-looking information contained in this document, these results or developments may not be a reliable indication of SEMCO Technologies' future results or developments. Readers are advised to carefully review the risk factors described in the registration document approved by the Autorité des Marchés Financiers ('AMF'), available free of charge on the Company's website. In the event that any or all of these risk factors or other factors materialise, SEMCO Technologies shall in no event be held liable for any decision or action taken in relation to the information and/or statements contained in this press release or for any damage related thereto. This information is provided solely as of the date of this press release. SEMCO Technologies does not undertake to publish updates to this information or the assumptions on which it is based, except where required by law or regulation. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for shares in SEMCO Technologies in any country. 1 ECM Technologies: A simplified joint stock company (478 969 173 RCS Grenoble), wholly owned by ECM Group (880 360 425 RCS Grenoble), itself 56.08% owned by LaMa, wholly owned by Mr Laurent PELISSIER (Chief Executive Officer of the Company), Ms Marlène PELISSIER (director of the Company) and their family. 2 LaMa: A limited liability company (Société à responsabilité limitée – 452 107 782 RCS Annecy), wholly owned by Mr. Laurent PELISSIER (Chairman and CEO of the Company), Mrs. Marlène PELISSIER (Director of the Company), and their family. 3 The situations or conditions leading to the suspension or termination of the liquidity contract, as specified in the liquidity contract, are as follows: Suspension of the contract: Under the conditions set out in Article 5 of the aforementioned AMF decision. At the initiative of the issuer in certain situations and, in particular, if the issuer no longer has authorisation to repurchase its own shares. Termination of the agreement: By the issuer, at any time, with three months' notice, under the conditions for closing the liquidity account provided for in the liquidity agreement. By the market maker, with 30 days' notice. The contract shall be automatically terminated if the parties are unable, in the situation provided for in Article 10 (liquidity account balance), to agree on how to proceed with the contract. By the facilitator if the Liquidity Provider contract between the facilitator and Euronext Paris is terminated. 4 Pro forma information for 2024 and comparative information including: (1) the sale of the 'Gas Components' business to ECM Components on 30/04/2024 and (2) the sale of shares in SEMCO Smartech Suzhou, a Chinese subsidiary, to another ECM Group subsidiary. Expand
Business Wire
28-07-2025
- Business
- Business Wire
Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia
PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains marketing authorization (MA) and reimbursement status for Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) in the Kingdom of Saudi Arabia (KSA). Marketing authorization for Sibnayal® (ADV7103) in distal Renal Tubular Acidosis (dRTA) in KSA has been granted, based on the European registration dossier. Furthermore, Saudi authorities have agreed a reimbursement rate in line with the best European pricing. This achievment results of a close collaboration between Advicenne and its local partner, Taïba Healthcare, a leading distributor of pharmaceutical products in the Gulf region. Advicenne will act as the marketing authorization holder, while Taïba Healthcare will manage local marketing activities. The incidence of dRTA is higher in Gulf countries than in Europe or the United States, and prevalence in KSA could be estimated around 600 to 800 patients. Sibnayal® is already prescribed through early access programs in several Gulf countries outside Saudi Arabia. This milestone paves the way for registrations in GCC countries where the application is filed. Didier Laurens, CEO of Advicenne, declared: 'I am particularly proud of this important achievement and wish to congratulate both Advicenne and Taïba Healthcare teams, whose efforts were instrumental in informing and convincing the Saudi health authorities. The reimbursement obtained, comparable to the highest levels recorded in Europe, further attests to the significant therapeutic value of Sibnayal® in a region with one of the highest prevalence rates of dRTA worldwide.' About Advicenne Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: Disclaimer This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.
